Literature DB >> 8915789

Bone density in Type 1 Gaucher disease.

G M Pastores1, S Wallenstein, R J Desnick, M M Luckey.   

Abstract

Skeletal involvement is a major source of complications in patients with Type 1 Gaucher disease. To investigate the bone density and potential usefulness of bone densitometry in Gaucher disease, dual-energy X-ray absorptiometry was used to measure the density of the lumbar spine, femoral neck, trochanter, and distal radius in 61 adult patients ranging in age from 22 to 77 years. The mean bone density at each site was significantly lower than expected for age and sex. The severity of the osteopenia correlated significantly with other clinical indicators of disease severity, including the N370S/84GG genotype, prior splenectomy, and hepatomegaly. The bone density measurements also correlated significantly with the severity of skeletal disease as assessed by skeletal radiography. Vertebral density remained an independent predictor of the severity of bone involvement even after controlling for age, sex, weight, genotype, splenectomy, and hepatomegaly. These findings suggest that bone density measurements provide a quantitative assessment of bone involvement in Type 1 Gaucher disease, which may permit serial, noninvasive monitoring of bone changes in this progressive disorder.

Entities:  

Mesh:

Year:  1996        PMID: 8915789     DOI: 10.1002/jbmr.5650111125

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  23 in total

1.  Quality of life assessment in adults with type 1 Gaucher disease.

Authors:  B J Masek; K B Sims; C M Bove; M S Korson; P Short; D K Norman
Journal:  Qual Life Res       Date:  1999-05       Impact factor: 4.147

Review 2.  Radiological aspects of Gaucher disease.

Authors:  Robert Katz; Tom Booth; Rikin Hargunani; Peter Wylie; Brian Holloway
Journal:  Skeletal Radiol       Date:  2010-07-25       Impact factor: 2.199

3.  Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy.

Authors:  G Ciana; R Addobbati; G Tamaro; A Leopaldi; M Nevyjel; L Ronfani; L Vidoni; M G Pittis; B Bembi
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

4.  Long-term bone mineral density response to enzyme replacement therapy in a retrospective pediatric cohort of Gaucher patients.

Authors:  Giovanni Ciana; Laura Deroma; Anna Martina Franzil; Andrea Dardis; Bruno Bembi
Journal:  J Inherit Metab Dis       Date:  2012-03-23       Impact factor: 4.982

5.  Therapeutic approaches for lysosomal storage diseases.

Authors:  Gregory M Pastores
Journal:  Ther Adv Endocrinol Metab       Date:  2010-08       Impact factor: 3.565

Review 6.  An overview on bone manifestations in Gaucher disease.

Authors:  Peter Mikosch; Derralynn Hughes
Journal:  Wien Med Wochenschr       Date:  2010-12

7.  Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.

Authors:  Pramod K Mistry; Neal J Weinreb; Paige Kaplan; J Alexander Cole; Andrea R Gwosdow; Thomas Hangartner
Journal:  Blood Cells Mol Dis       Date:  2010-11-26       Impact factor: 3.039

Review 8.  Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring.

Authors:  T M Cox; J M F G Aerts; N Belmatoug; M D Cappellini; S vom Dahl; J Goldblatt; G A Grabowski; C E M Hollak; P Hwu; M Maas; A M Martins; P K Mistry; G M Pastores; A Tylki-Szymanska; J Yee; N Weinreb
Journal:  J Inherit Metab Dis       Date:  2008-05-23       Impact factor: 4.982

Review 9.  Gaucher disease: pediatric concerns.

Authors:  Deborah Elstein; Aya Abrahamov; Altoon Dweck; Irith Hadas-Halpern; Ari Zimran
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

10.  Molecular aspects of osteopathy in type 1 Gaucher disease: correlation between genetics and bone density.

Authors:  Efrat Arnheim; Gaya Chicco; Mici Phillips; Ehud Lebel; A Joseph Foldes; Menachem Itzchaki; Deborah Elstein; Ari Zimran; Gheona Altarescu
Journal:  Rheumatol Int       Date:  2008-03-04       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.